Catalyst Pharmaceuticals, Inc. (CPRX): Key Legal Update – FIRDAPSE® Patent Trial Delayed

Summary of Key Points

• District Court Delays FIRDAPSE® Patent Trial: On March 18, 2026, Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) announced that the District Court for the District of New Jersey issued an order delaying the start of the bench trial between Catalyst and Hetero USA, Inc. The trial, which was originally scheduled to begin on March 23, 2026, is now set to commence on May 18, 2026.
• Focus of the Trial: The litigation centers on the validity of Catalyst’s Orange Book-listed patents for FIRDAPSE® (amifampridine), which are set to expire in 2032, 2034, and 2037.
• Patents at Stake: The patents in question provide market exclusivity for FIRDAPSE®, Catalyst’s flagship product.
• Delay Notification: The company was notified of the court’s decision on March 18, 2026, and this information is disclosed as a material event.

Details and Investor Implications

FIRDAPSE® is Catalyst’s primary revenue-generating product, indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder. The outcome of this trial is crucial as it will determine the ongoing exclusivity and commercial prospects for FIRDAPSE®. The patents in dispute are a cornerstone for the company’s revenue stream through at least 2037, assuming they are upheld.

Shareholder and Market Sensitivity:

• Patent Litigation is Highly Price Sensitive: The outcome of this trial could be a significant market-moving event. If Catalyst prevails and maintains patent protection, the company preserves its exclusive market position for FIRDAPSE®. If the patents are invalidated, the door opens for generic competition, potentially resulting in a substantial reduction in revenue and downward pressure on the share price.
• Delay Impact: While the delay itself does not indicate the likely outcome of the trial, it extends the period of uncertainty. Investors should be aware that such legal uncertainties can lead to increased volatility in CPRX’s share price as the new trial date approaches.
• No Indication of Settlement: The company has not disclosed any settlement discussions or resolutions, so the risk of an adverse outcome remains present.

Company Information

• Company Name: Catalyst Pharmaceuticals, Inc.
• Ticker Symbol: CPRX
• Exchange: NASDAQ Capital Market
• Address: 355 Alhambra Circle, Suite 801, Coral Gables, FL 33134
• Telephone: (305) 420-3200
• Incorporated in: Delaware

Actionable Takeaways for Investors

• Monitor the Upcoming Trial: The outcome, now expected in or after May 2026, will have direct implications for Catalyst’s earnings and long-term value.
• Expect Volatility: Legal and patent uncertainties can cause significant share price swings, especially as the new trial date approaches.
• FIRDAPSE® Exclusivity is Critical: Investors should recognize that a loss of exclusivity due to patent invalidation could have a profound negative impact on the company’s valuation.

Conclusion

The delay in the FIRDAPSE® patent litigation is a material development for Catalyst Pharmaceuticals and its investors. The trial’s outcome will be a pivotal factor in determining the company’s future revenue and competitive positioning. Investors should remain alert to further updates, as any news regarding the litigation could significantly affect the share price.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence or consult with a licensed financial advisor before making any investment decisions. The information presented is based on company filings as of March 18, 2026, and may be subject to change.

View CATALYST PHARMACEUTICALS, INC. Historical chart here